PAVmed Inc
F:1P5

Watchlist Manager
PAVmed Inc Logo
PAVmed Inc
F:1P5
Watchlist
Price: 2.64 EUR Market Closed
Market Cap: €294.1m

Wall St Price Targets

1P5 Price Targets Summary
PAVmed Inc

Wall Street analysts forecast 1P5 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 1P5 is 18.69 EUR with a low forecast of 7.31 EUR and a high forecast of 30.88 EUR.

Lowest Forecast
Price Target
7.31 EUR
177% Upside
Average Forecast
Price Target
18.69 EUR
608% Upside
Highest Forecast
Price Target
30.88 EUR
1 070% Upside
PAVmed Inc Competitors:
Price Targets
PMVP
PMV Pharmaceuticals Inc
318% Upside
NKTX
Nkarta Inc
350% Upside
CBAN
Colony Bankcorp Inc
21% Upside

Revenue
Forecast

N/A
Past Growth
206% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss
N/A
Past Growth
206% / Year
Estimated Growth
Estimates Accuracy
-22%
Average Miss

The compound annual growth rate for Revenue over the next 2 years is 206%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-97%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-97%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 1P5's stock price target?
Price Target
18.69 EUR

According to Wall Street analysts, the average 1-year price target for 1P5 is 18.69 EUR with a low forecast of 7.31 EUR and a high forecast of 30.88 EUR.

What is the Revenue forecast for PAVmed Inc?
Projected CAGR
206%

The compound annual growth rate for Revenue over the next 2 years is 206%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett